PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
44.115
-0.165 (-0.37%)
As of 3:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close44.280
Open44.280
Bid44.120 x 800
Ask44.130 x 900
Day's Range43.900 - 44.550
52 Week Range33.200 - 45.810
Volume13,248,762
Avg. Volume21,520,335
Market Cap255.005B
Beta (3Y Monthly)0.73
PE Ratio (TTM)11.14
EPS (TTM)3.959
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.07%)
Ex-Dividend Date2018-11-08
1y Target Est43.74
Trade prices are not sourced from all markets
  • MARKETS:  Oil heading into bear market territory
    Yahoo Finance Video5 days ago

    MARKETS: Oil heading into bear market territory

    Oil moving on a government report on supply increases. Yahoo Finance's Julie Hyman and Adam Shapiro talk to Seana Smith on the floor of the NYSE.

  • MARKETS:  Pharma stocks making moves ahead of midterms
    Yahoo Finance Video6 days ago

    MARKETS: Pharma stocks making moves ahead of midterms

    Stocks moving higher on election days with Mechanicals and Pharma making biggest moves. Yahoo Finance's Adam Shapiro and Julie Hyman talk with Seana Smith at the NYSE.

  • Corbus Pharmaceuticals Holdings’ Performance in 2018
    Market Realist5 hours ago

    Corbus Pharmaceuticals Holdings’ Performance in 2018

    Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.

  • How Nektar Performed in the Third Quarter
    Market Realist7 hours ago

    How Nektar Performed in the Third Quarter

    Nektar Therapeutics (NKTR) released its third-quarter results on November 8. On November 6, Nektar announced a clinical oncology collaboration with Pfizer (PFE) to evaluate the combination of NKTR-214 with avelumab and talazoparib in different cancer areas. Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the comparable period of 2017.

  • Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)
    Insider Monkeyyesterday

    Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)

    The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]

  • Better Buy: Amgen Inc. vs. Pfizer Inc.
    Motley Foolyesterday

    Better Buy: Amgen Inc. vs. Pfizer Inc.

    Which big drugmaker is the better pick for long-term investors?

  • Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
    Zacks3 days ago

    Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

    Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

  • ICU Medical Inc (ICUI) Q3 2018 Earnings Conference Call Transcript
    Motley Fool4 days ago

    ICU Medical Inc (ICUI) Q3 2018 Earnings Conference Call Transcript

    ICUI earnings call for the period ending September 30, 2018.

  • Investor's Business Daily5 days ago

    These 5 Dow Jones Stocks Just Made This Bullish Move

    United Health and Microsoft led the Dow Jones stocks rally — two among five Dow stocks reclaiming the 50-day moving average.

  • Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
    Zacks4 days ago

    Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up

    Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.

  • How Analysts Rate AbbVie Stock
    Market Realist4 days ago

    How Analysts Rate AbbVie Stock

    In November 2018, of the total 20 analysts covering AbbVie (ABBV), eight analysts have given the stock a “buy” or higher rating, nine analysts have given it a “hold” rating, and three analysts have given AbbVie a “sell” or a lower rating. The mean rating for AbbVie stock is 2.6 with a target price of $101.11, implying an upside potential of 20.9% over AbbVie’s closing price of $83.66 on November 7.

  • Reuters4 days ago

    AstraZeneca sees years of growth as drug sales turn corner

    Strong demand for AstraZeneca's new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement. Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018. It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which staved off a takeover bid from Pfizer four years ago, rose 2 percent by 0920 GMT on Thursday.

  • What AbbVie’s Bottom Line Trend Indicates
    Market Realist5 days ago

    What AbbVie’s Bottom Line Trend Indicates

    AbbVie’s net earnings per share were $1.01 in the third quarter of 2017. AbbVie stock corrected from $123.21 on January 26, 2018, to $89.78 on April 6, 2018. Amidst the broader market turmoil in October, AbbVie stock witnessed selling pressure and fell to $77.85 on October 31.

  • How AbbVie Is Positioned in November
    Market Realist5 days ago

    How AbbVie Is Positioned in November

    AbbVie (ABBV) operates in four therapeutic areas: immunology, oncology, virology, and neuroscience. Strong performances from AbbVie’s hematologic oncology product portfolio, solid Humira and Imbruvica sales, and stock price fluctuations have kept investors interested in the stock. In this series, we explore AbbVie’s financials, the performance of the company’s key products, analysts’ recommendations for the stock, and the company’s valuation metrics.

  • A Look at AbbVie’s Operational Performance
    Market Realist5 days ago

    A Look at AbbVie’s Operational Performance

    AbbVie’s (ABBV) cost of products sold increased from $1.62 billion in the third quarter of 2017 to $1.83 billion in the third quarter of 2018. For fiscal 2018 and 2019, AbbVie’s gross margins are expected at 80.63% and 82.11%, respectively, as compared with gross margins of 80.47% for fiscal 2017. In comparison, fiscal 2018 gross margins of peers Johnson & Johnson (JNJ), Eli Lilly (LLY), and Pfizer (PFE) are expected at 70.43%, 75.98%, and 79.20%, respectively.

  • Investing.com5 days ago

    Pfizer Rises 3%

    Investing.com - Pfizer (NYSE:PFE) rose by 3.29% to trade at $44.42 by 10:41 (15:41 GMT) on Wednesday on the NYSE exchange.

  • CNBC5 days ago

    'We have a lot of things in common' — Trump wants to work with Democrats on infrastructure, drugs

    President Trump says at a White House press conference he hopes to work together with congressional Democrats on issues ranging from infrastructure to drug pricing. "The Democrats will come to us with a plan for infrastructure, a plan for health care, a plan for whatever they're looking at and we'll negotiate," the president says. President Donald Trump said at a White House press conference Wednesday he hopes to work with congressional Democrats on issues ranging from infrastructure to drug pricing.

  • Benzinga5 days ago

    Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election

    Democrats didn’t get the blue wave they hoped for Tuesday, but they picked up enough votes to take the majority in the House of Representatives, with Republicans maintaining control of the Senate. A Democratic House could provide some resistance to President Donald Trump’s trade war tariffs on China. The potential for Democrats to pressure Trump to back down on China is theoretically good news for U.S. companies that rely on Chinese supply and demand.

  • Moody's5 days ago

    NMC Healthcare Sukuk Limited -- Moody's assigns Ba1 rating to NMC's trust certificates

    Moody's Investors Service has today assigned a Ba1 rating to the proposed USD-denominated trust certificates (or sukuk) of NMC Healthcare Sukuk Limited. At the same time Moody's assigned a stable outlook ...

  • Why Pfizer’s Rare Disease Portfolio Offers a Unique Opportunity
    Market Realist5 days ago

    Why Pfizer’s Rare Disease Portfolio Offers a Unique Opportunity

    Of this revenue, $157 million came from the US market, reflecting a YoY fall of 3%. The rare disease franchise earned revenue of $201 million from developed European markets, $90 million from other developed markets, and $83 million from emerging markets.

  • Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
    Zacks6 days ago

    Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

    Pfizer (PFE) closed the most recent trading day at $42.99, moving -1.22% from the previous trading session.

  • TheStreet.com6 days ago

    Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

    is better off than many other drug makers ahead of contentious midterms that could provoke ramped-up regulation. "Pricing was a bit of a drag this quarter," CEO David Ricks told CNBC. The conservative pricing approach comes as the Trump administration and many liberal candidates favor regulation and transparency in drug pricing, a rare point of agreement.

  • Vaccines Are an Important Growth Driver for Pfizer
    Market Realist6 days ago

    Vaccines Are an Important Growth Driver for Pfizer

    Of this revenue, $1.15 billion was earned from the US market, reflecting a YoY rise of 14%. The business earned revenue of $229 million from developed European markets, $103 million from other developed markets, and $363 million from emerging markets.

  • Xeljanz: PFE’s Immunology and Inflammation Growth Driver
    Market Realist6 days ago

    Xeljanz: PFE’s Immunology and Inflammation Growth Driver

    Of this revenue, $332 million was earned from the US market, up 14% YoY. Xeljanz reported $30 million worth of revenue from developed European markets, $41 million from other developed markets, and the remaining $29 million from emerging markets.

  • PR Newswire6 days ago

    New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

    SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).